Online inquiry

IVTScrip™ mRNA-Anti-DLL4&VEGFA, OMP-305B83(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ12715MR)

This product GTTS-WQ12715MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets DLL4&VEGFA gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Chimeric; Humanized
RefSeq NM_019074.4; NM_001025366.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 54567; 7422
UniProt ID Q9NR61; P15692
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-DLL4&VEGFA, OMP-305B83(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ12715MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ12411MR IVTScrip™ mRNA-Anti-CD3E, NI-0401(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA NI-0401
GTTS-WQ14455MR IVTScrip™ mRNA-Anti-IGF1R, RO4858696-000(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA RO4858696-000
GTTS-WQ15538MR IVTScrip™ mRNA-Anti-TGM2, UCB-7858(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA UCB-7858
GTTS-WQ476MR IVTScrip™ mRNA-Anti-SELP, 42-89-glycoprotein(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA 42-89-glycoprotein
GTTS-WQ98MR IVTScrip™ mRNA-Anti-KDR, 1121B(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA 1121B
GTTS-WQ33MR IVTScrip™ mRNA-Anti-S, 2130(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA 2130
GTTS-WQ14078MR IVTScrip™ mRNA-Anti-DLL4, REGN-421(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA REGN-421
GTTS-WQ9068MR IVTScrip™ mRNA-Anti-IGF1R, IMC-A12(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA IMC-A12
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW